FREDERICK, Md., Dec. 20, 2018 /PRNewswire-PRWeb/ -- RoosterBio Inc., a leading supplier of human Mesenchymal Stem/Stromal Cell (hMSC) biomanufacturing systems, will be attending the 37th Annual J.P. Morgan Healthcare Conference, 7-10 January 2019 in San Francisco, California.
RoosterBio has achieved several important milestones in 2018 while they have expanded their management team. RoosterBio launched multiple new products which include the CliniControl™ adult-derived hMSCs and paired media systems, both produced under U.S. Food and Drug Administration (FDA) regulation and current Good Manufacturing Practices (cGMPs). They have also expanded their xeno-free (XF) development grade product portfolio to include Plug-and-Play XF Bioreactor Bundles and "Ready-to-Print" RoosterRTP™ cells. RoosterBio also completed submission of an FDA Type II Master File for its CliniControl line of cGMP hMSC working cell banks to complement the 2017 Master File for the CliniControl RoosterNourish™-MSC-CC bioprocess media. These milestones are helping to advance the rapidly growing $67 billion regenerative medicine industry.
"2018 has been a breakout year for our dedicated team at RoosterBio, and we are forecasting continued rapid growth in 2019," said RoosterBio CEO, Margot Connor. "We look forward to sharing the good news about RoosterBio with attendees of The J.P. Morgan Healthcare Conference." Connor will be joined at the conference by Founder and Chief Product Officer, Jon Rowley, Ph.D. and CFO, Rick Sullivan.
Those attending the J.P. Morgan Healthcare Conference and wishing to arrange a discussion with RoosterBio leadership may do so at [email protected].
About RoosterBio, Inc.: RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog "Democratizing Cell Technologies" (http://www.roosterbio.blogspot.com).
SOURCE RoosterBio, Inc.
Advertisement
RoosterBio has achieved several important milestones in 2018 while they have expanded their management team. RoosterBio launched multiple new products which include the CliniControl™ adult-derived hMSCs and paired media systems, both produced under U.S. Food and Drug Administration (FDA) regulation and current Good Manufacturing Practices (cGMPs). They have also expanded their xeno-free (XF) development grade product portfolio to include Plug-and-Play XF Bioreactor Bundles and "Ready-to-Print" RoosterRTP™ cells. RoosterBio also completed submission of an FDA Type II Master File for its CliniControl line of cGMP hMSC working cell banks to complement the 2017 Master File for the CliniControl RoosterNourish™-MSC-CC bioprocess media. These milestones are helping to advance the rapidly growing $67 billion regenerative medicine industry.
Advertisement
"2018 has been a breakout year for our dedicated team at RoosterBio, and we are forecasting continued rapid growth in 2019," said RoosterBio CEO, Margot Connor. "We look forward to sharing the good news about RoosterBio with attendees of The J.P. Morgan Healthcare Conference." Connor will be joined at the conference by Founder and Chief Product Officer, Jon Rowley, Ph.D. and CFO, Rick Sullivan.
Those attending the J.P. Morgan Healthcare Conference and wishing to arrange a discussion with RoosterBio leadership may do so at [email protected].
About RoosterBio, Inc.: RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog "Democratizing Cell Technologies" (http://www.roosterbio.blogspot.com).
SOURCE RoosterBio, Inc.
